A healthtech business tackling diabetes has secured £500,000 of funding from the US less than a year after its full launch.

Founded by Cambridge University scientist Mike Gibbs and Oxford University engineer Chris Edson OurPath, aims to encourage lifestyle changes among those at risk of developing type 2 diabetes.

To do this, it has developed a programme which combines live support with educational content.

READ MORE: Windfarm backed by actor Michael Sheen wins £5.25m investment

According to Bdaily, funding has come from American VC 500 Startups along with Bethnal Green Ventures and unnamed private angel investors.

OurPath’s six week programme combines activity trackers and wireless scales to help the one in three people in the UK who ave pre-diabetes due to inactive lifestyles and poor diets.

It is estimated 70 per cent of those will develop type 2 diabetes in the future if they don’t change.

The programme, currently available to consumers for a flat £149 fee, monitors weight and activity levels in tandem with diet plans and daily interactive content.

OurPath is the first-ever behavioural change programme to be commissioned by the NHS.